Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells.

Hadinger KP, Marshalek JP, Sheeran PS, Dayton PA, Matsunaga TO.

Ultrasound Med Biol. 2018 Dec;44(12):2728-2738. doi: 10.1016/j.ultrasmedbio.2018.08.003. Epub 2018 Sep 15.

PMID:
30228045
2.

Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging.

Weinkauf CC, Concha-Moore K, Lindner JR, Marinelli ER, Hadinger KP, Bhattacharjee S, Berman SS, Goshima K, Leon LR Jr, Matsunaga TO, Unger E.

J Vasc Surg. 2018 Dec;68(6S):105S-113S. doi: 10.1016/j.jvs.2017.10.088. Epub 2018 Feb 13.

PMID:
29452833
3.

Optically and acoustically triggerable sub-micron phase-change contrast agents for enhanced photoacoustic and ultrasound imaging.

Lin S, Shah A, Hernández-Gil J, Stanziola A, Harriss BI, Matsunaga TO, Long N, Bamber J, Tang MX.

Photoacoustics. 2017 Apr 11;6:26-36. doi: 10.1016/j.pacs.2017.04.001. eCollection 2017 Jun.

4.

Intracellular delivery and ultrasonic activation of folate receptor-targeted phase-change contrast agents in breast cancer cells in vitro.

Marshalek JP, Sheeran PS, Ingram P, Dayton PA, Witte RS, Matsunaga TO.

J Control Release. 2016 Dec 10;243:69-77. doi: 10.1016/j.jconrel.2016.09.010. Epub 2016 Sep 26.

5.

Methods of Generating Submicrometer Phase-Shift Perfluorocarbon Droplets for Applications in Medical Ultrasonography.

Sheeran PS, Matsuura N, Borden MA, Williams R, Matsunaga TO, Burns PN, Dayton PA.

IEEE Trans Ultrason Ferroelectr Freq Control. 2017 Jan;64(1):252-263. doi: 10.1109/TUFFC.2016.2619685. Epub 2016 Oct 20.

6.

Imaging of targeted lipid microbubbles to detect cancer cells using third harmonic generation microscopy.

Harpel K, Baker RD, Amirsolaimani B, Mehravar S, Vagner J, Matsunaga TO, Banerjee B, Kieu K.

Biomed Opt Express. 2016 Jun 28;7(7):2849-60. doi: 10.1364/BOE.7.002849. eCollection 2016 Jul 1.

7.

A novel small molecule inhibitor of the DNA repair protein Ku70/80.

Weterings E, Gallegos AC, Dominick LN, Cooke LS, Bartels TN, Vagner J, Matsunaga TO, Mahadevan D.

DNA Repair (Amst). 2016 Jul;43:98-106. doi: 10.1016/j.dnarep.2016.03.014. Epub 2016 Apr 7.

PMID:
27130816
8.

Quantifying activation of perfluorocarbon-based phase-change contrast agents using simultaneous acoustic and optical observation.

Li S, Lin S, Cheng Y, Matsunaga TO, Eckersley RJ, Tang MX.

Ultrasound Med Biol. 2015 May;41(5):1422-31. doi: 10.1016/j.ultrasmedbio.2014.12.021. Epub 2015 Feb 2.

9.

Phase change events of volatile liquid perfluorocarbon contrast agents produce unique acoustic signatures.

Sheeran PS, Matsunaga TO, Dayton PA.

Phys Med Biol. 2014 Jan 20;59(2):379-401. doi: 10.1088/0031-9155/59/2/379. Epub 2013 Dec 19.

10.

Phase-shift perfluorocarbon agents enhance high intensity focused ultrasound thermal delivery with reduced near-field heating.

Phillips LC, Puett C, Sheeran PS, Wilson Miller G, Matsunaga TO, Dayton PA.

J Acoust Soc Am. 2013 Aug;134(2):1473-82. doi: 10.1121/1.4812866. Erratum in: J Acoust Soc Am. 2013 Dec;134(6):4575.

11.

Phase-transition thresholds and vaporization phenomena for ultrasound phase-change nanoemulsions assessed via high-speed optical microscopy.

Sheeran PS, Matsunaga TO, Dayton PA.

Phys Med Biol. 2013 Jul 7;58(13):4513-34. doi: 10.1088/0031-9155/58/13/4513. Epub 2013 Jun 13.

12.

A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents.

Cárdenas-Rodríguez J, Howison CM, Matsunaga TO, Pagel MD.

Magn Reson Imaging. 2013 Jul;31(6):900-10. doi: 10.1016/j.mri.2012.12.002. Epub 2013 Apr 11.

13.

Toward ultrasound molecular imaging with phase-change contrast agents: an in vitro proof of principle.

Sheeran PS, Streeter JE, Mullin LB, Matsunaga TO, Dayton PA.

Ultrasound Med Biol. 2013 May;39(5):893-902. doi: 10.1016/j.ultrasmedbio.2012.11.017. Epub 2013 Feb 27.

14.

Phase-change nanoparticles using highly volatile perfluorocarbons: toward a platform for extravascular ultrasound imaging.

Matsunaga TO, Sheeran PS, Luois S, Streeter JE, Mullin LB, Banerjee B, Dayton PA.

Theranostics. 2012;2(12):1185-98. doi: 10.7150/thno.4846. Epub 2012 Dec 23. Review.

15.

Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons.

Sheeran PS, Luois SH, Mullin LB, Matsunaga TO, Dayton PA.

Biomaterials. 2012 Apr;33(11):3262-9. doi: 10.1016/j.biomaterials.2012.01.021. Epub 2012 Jan 29.

16.

Decafluorobutane as a phase-change contrast agent for low-energy extravascular ultrasonic imaging.

Sheeran PS, Wong VP, Luois S, McFarland RJ, Ross WD, Feingold S, Matsunaga TO, Dayton PA.

Ultrasound Med Biol. 2011 Sep;37(9):1518-30. doi: 10.1016/j.ultrasmedbio.2011.05.021. Epub 2011 Jul 19.

17.

Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound.

Sheeran PS, Luois S, Dayton PA, Matsunaga TO.

Langmuir. 2011 Sep 6;27(17):10412-20. doi: 10.1021/la2013705. Epub 2011 Jul 28.

18.

In vitro and in vivo transfection of primary phagocytes via microbubble-mediated intraphagosomal sonoporation.

Lemmon JC, McFarland RJ, Rybicka JM, Balce DR, McKeown KR, Krohn RM, Matsunaga TO, Yates RM.

J Immunol Methods. 2011 Aug 31;371(1-2):152-8. doi: 10.1016/j.jim.2011.06.001. Epub 2011 Jun 14.

PMID:
21693123
19.

In vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchange.

Johnson JL, Dolezal MC, Kerschen A, Matsunaga TO, Unger EC.

Artif Cells Blood Substit Immobil Biotechnol. 2009;37(4):156-62. doi: 10.1080/10731190903043192. Epub 2009 Jun 22.

PMID:
19548131
20.

Therapeutic effects of paclitaxel-containing ultrasound contrast agents.

Tartis MS, McCallan J, Lum AF, LaBell R, Stieger SM, Matsunaga TO, Ferrara KW.

Ultrasound Med Biol. 2006 Nov;32(11):1771-80.

PMID:
17112963
21.

Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy.

Dayton PA, Zhao S, Bloch SH, Schumann P, Penrose K, Matsunaga TO, Zutshi R, Doinikov A, Ferrara KW.

Mol Imaging. 2006 Jul;5(3):160-74.

22.

A method for radiation-force localized drug delivery using gas-filled lipospheres.

Shortencarier MJ, Dayton PA, Bloch SH, Schumann PA, Matsunaga TO, Ferrara KW.

IEEE Trans Ultrason Ferroelectr Freq Control. 2004 Jul;51(7):822-31.

PMID:
15301001
23.

Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells.

Dayton PA, Pearson D, Clark J, Simon S, Schumann PA, Zutshi R, Matsunaga TO, Ferrara KW.

Mol Imaging. 2004 Apr;3(2):125-34.

24.

Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi.

Schumann PA, Christiansen JP, Quigley RM, McCreery TP, Sweitzer RH, Unger EC, Lindner JR, Matsunaga TO.

Invest Radiol. 2002 Nov;37(11):587-93.

PMID:
12393970
25.

Biomedical implications of a thrombus-specific US contrast agent.

Unger EC, Matsunaga TO, McCreery TP, Sweitzer RH.

Acad Radiol. 2002 May;9 Suppl 1:S56-7. No abstract available.

PMID:
12019895
26.

Therapeutic applications of microbubbles.

Unger EC, Matsunaga TO, McCreery T, Schumann P, Sweitzer R, Quigley R.

Eur J Radiol. 2002 May;42(2):160-8. Review.

PMID:
11976013
27.

Local drug and gene delivery through microbubbles.

Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T.

Prog Cardiovasc Dis. 2001 Jul-Aug;44(1):45-54. Review.

PMID:
11533926
28.

Gadolinium-containing copolymeric chelates--a new potential MR contrast agent.

Unger EC, Shen D, Wu G, Stewart L, Matsunaga TO, Trouard TP.

MAGMA. 1999 Aug;8(3):154-62.

PMID:
10504042
29.

Interaction of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin with delta-opioid receptor subtypes in vivo.

Vanderah T, Takemori AE, Sultana M, Portoghese PS, Mosberg HI, Hruby VJ, Haaseth RC, Matsunaga TO, Porreca F.

Eur J Pharmacol. 1994 Feb 3;252(2):133-7.

30.

Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity.

Fang L, Knapp RJ, Horvath R, Matsunaga TO, Haaseth RC, Hruby VJ, Porreca F, Yamamura HI.

J Pharmacol Exp Ther. 1994 Feb;268(2):836-46.

PMID:
8113996
31.

The actions of melanin-concentrating hormone (MCH) on passive avoidance in rats: a preliminary study.

McBride RB, Beckwith BE, Swenson RR, Sawyer TK, Hadley ME, Matsunaga TO, Hruby VJ.

Peptides. 1994;15(4):757-9.

PMID:
7937355
32.

Comparison of the membrane-bound states of two structurally similar delta-selective opioid peptides by transferred nuclear Overhauser effect spectroscopy and molecular modeling.

Matsunaga TO, Collins N, Ramaswami V, Yamamura SH, O'Brien DF, Hruby VJ.

Biochemistry. 1993 Dec 7;32(48):13180-9. Erratum in: Biochemistry 1994 May 3;33(17):5356.

PMID:
8241172
33.

Pseudoirreversible binding characteristics of [D-Ala2,Glu4]deltorphin and its Cys4 substituted derivative to delta-opioid receptors.

Wild KD, Horan PJ, Misicka A, Lipkowski A, Haaseth RC, Matsunaga TO, Hruby VJ, Toth G, Borsodi A, Yamamura HI, et al.

Eur J Pharmacol. 1993 Jun 15;246(1):25-31.

PMID:
8394818
34.

alpha-MSH and MCH are functional antagonists in a central nervous system auditory gating paradigm.

Miller CL, Hruby VJ, Matsunaga TO, Bickford PC.

Ann N Y Acad Sci. 1993 May 31;680:571-4. No abstract available.

PMID:
8390195
35.

Alpha-MSH and MCH are functional antagonists in a CNS auditory gating paradigm.

Miller CL, Hruby VJ, Matsunaga TO, Bickford PC.

Peptides. 1993 May-Jun;14(3):431-40.

PMID:
8392716
36.

Enzymological studies of melanin concentrating hormone (MCH) and related analogues.

Castrucci AM, Visconti MA, Matsunaga TO, Hadley ME, Hruby VJ.

Comp Biochem Physiol B. 1992 Oct;103(2):317-20.

PMID:
1424563
37.

Opioid peptide interactions with lipid bilayer membranes.

Ramaswami V, Haaseth RC, Matsunaga TO, Hruby VJ, O'Brien DF.

Biochim Biophys Acta. 1992 Aug 24;1109(2):195-202. Erratum in: Biochim Biophys Acta 1992 Oct 19;1111(1):143.

PMID:
1520696
38.

Synthesis and bioactivity studies of two isosteric acyclic analogues of melanin concentrating hormone.

Matsunaga TO, Hruby VJ, Lebl M, Castrucci AM, Hadley ME.

Life Sci. 1992;51(9):679-85.

PMID:
1501512
39.

Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity.

Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ, Porreca F.

Life Sci. 1992;50(20):1535-41.

PMID:
1315897
40.

Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro.

Kramer TH, Toth G, Haaseth RC, Matsunaga TO, Davis P, Hruby VJ, Burks TF.

Life Sci. 1991;48(9):881-6.

PMID:
1847736
41.

Conformational analysis of opioid receptor-selective peptides using nuclear magnetic resonance and theoretical calculations.

Hruby VJ, Prakash O, Kazmierski W, Gehrig C, Matsunaga TO.

NIDA Res Monogr. 1991;112:198-217. Review. No abstract available.

PMID:
1661378
42.

1H-NMR assignments and conformational studies of melanin concentrating hormone in water using two-dimensional NMR.

Matsunaga TO, Gehrig CA, Hruby VJ.

Biopolymers. 1990;30(13-14):1291-5. No abstract available.

PMID:
1964810
43.

Melanin concentrating hormone (MCH): structure-function aspects of its melanocyte stimulating hormone-like (MSH-like) activity.

Matsunaga TO, Hruby VJ, Lebl M, Castrucci AM, Hadley ME.

Peptides. 1989 Jul-Aug;10(4):773-8.

PMID:
2587419
44.

Formation and utilization of formyl phosphate by N10-formyltetrahydrofolate synthetase: evidence for formyl phosphate as an intermediate in the reaction.

Mejillano MR, Jahansouz H, Matsunaga TO, Kenyon GL, Himes RH.

Biochemistry. 1989 Jun 13;28(12):5136-45.

PMID:
2548602
45.

Melanin concentrating hormone (MCH): synthesis and bioactivity studies of MCH fragment analogues.

Matsunaga TO, Castrucci AM, Hadley ME, Hruby VJ.

Peptides. 1989 Mar-Apr;10(2):349-54.

PMID:
2755875
46.

Melanin concentrating hormone. III. Melanin concentrating hormone (MCH): the message sequence.

Castrucci AM, Lebl M, Hruby VJ, Matsunaga TO, Hadley ME.

Life Sci. 1989;45(13):1141-8.

PMID:
2796600
47.

Isotope exchange as a probe of the kinetic mechanism of pyrophosphate-dependent phosphofructokinase.

Cho YK, Matsunaga TO, Kenyon GL, Bertagnolli BL, Cook PF.

Biochemistry. 1988 May 3;27(9):3320-5.

PMID:
2839232

Supplemental Content

Loading ...
Support Center